Daiichi Sankyo Company, Limited's latest marketcap:
As of 07/05/2025, Daiichi Sankyo Company, Limited's market capitalization has reached $41.61 B. According to our data, Daiichi Sankyo Company, Limited is the 532th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 41.61 B |
| Revenue (ttm) | 13.05 B |
| Net Income (ttm) | 2.05 B |
| Shares Out | 1.87 B |
| EPS (ttm) | 1.08 |
| Forward PE | 20.12 |
| Ex-Dividend Date | 03/28/2025 |
| Earnings Date | 07/31/2025 |
Daiichi Sankyo Company, Limited's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | ¥41.61 B | -26.54% | 532 |
| 12/30/2024 | ¥8.2 T | 10.41% | 367 |
| 12/29/2023 | ¥7.42 T | -8.87% | 330 |
| 12/30/2022 | ¥8.15 T | 45.32% | 228 |
| 12/30/2021 | ¥5.61 T | -18.22% | 392 |
| 12/30/2020 | ¥6.86 T | 46.38% | 222 |
| 12/30/2019 | ¥4.68 T | 105.92% | 310 |
| 12/28/2018 | ¥2.27 T | 17.68% | 560 |
| 12/29/2017 | ¥1.93 T | 21.86% | 758 |
| 12/30/2016 | ¥1.59 T | -7.56% | 765 |
Company Profile
About Daiichi Sankyo Company, Limited
Daiichi Sankyo Company, Limited is a global pharmaceutical company headquartered in Tokyo, Japan. Founded in 1899, the company specializes in manufacturing and selling pharmaceutical products across Japan, North America, Europe, and other international markets.
Key Products and Treatments
- Oncology: Enhertu (HER2-positive cancers), Turalio (CSF1R/KIT/FLT3-ITD mutations), Vanflyta (acute myeloid leukemia).
- Cardiovascular & Metabolic: Liziana, Savaysa (direct factor Xa inhibitors), Minnebro, Olmetec (antihypertensives), Nilemdo (cholesterol-lowering), Nustendi (bempedoic acid/ezetimibe).
- Neurology & Pain Management: Emgalty, Reyvow (migraine), Vimpat (anti-seizure), Tarlige (neuropathic pain).
- Hematology & Bone Health: Injectafer (iron deficiency), Pralia (osteoporosis), Ranmark (bone metastasis complications).
- Vaccines: COVID-19, influenza, measles/rubella, mumps, and H5N1 vaccines.
Strategic Collaborations
The company partners with Merck & Co., Inc. and AstraZeneca UK Limited to develop innovative anti-cancer drugs, enhancing its global oncology portfolio.
With over a century of expertise, Daiichi Sankyo continues to advance healthcare through cutting-edge research and patient-focused solutions.
Frequently Asked Questions
-
What is Daiichi Sankyo Company, Limited's (TYO-4568) current market cap?As of 07/05/2025, Daiichi Sankyo Company, Limited (including the parent company, if applicable) has an estimated market capitalization of $41.61 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Daiichi Sankyo Company, Limited (TYO-4568) rank globally by market cap?Daiichi Sankyo Company, Limited global market capitalization ranking is approximately 532 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.